Virtual Library
Start Your Search
Yan Wang
Author of
-
+
JICC01 - Joint IASLC-CAALC-CSCO Session: The Truth and Myth of Oral Anti-VEGFR Inhibitors for Advance NSCLC (ID 276)
- Event: WCLC 2020
- Type: Workshop
- Track: N.A.
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 07:00 - 09:00, Scientific Program Auditorium
-
+
JICC01.15 - Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study (ID 4274)
07:00 - 09:00 | Presenting Author(s): Yan Wang
- Abstract
- Presentation
Introduction
Currently, there has been no approved tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) harboring HER2 mutations, resulting in an unmet need of this molecular entity. We performed this phase II study to assess the efficacy and safety of pyrotinib combined with apatinib in HER2-mutant advanced NSCLC patients who had failed to prior treatment.
Methods
Patients with metastatic HER2-mutant lung adenocarcinomas who had been pretreated with chemotherapy or other TKIs were enrolled to administer pyrotinib (dose of 400mg once daily) in combination with apatinib (dose of 250mg once daily) for 28-day cycles. The primary endpoint was objective response rate (ORR), and the second endpoint included progression-free survival (PFS), duration of response (DoR), disease control rate (DCR), overall survival (OS) and safety. The trial was approved by ethics committee and registered to Chinese Clinical Trial Registry (ChiCTR1900021684). All participants of this study provided written informed consent.
Results
Between March 5, 2019, and January 20, 2020, 14 patients were enrolled and received pyrotinib with apatinib combination therapy, and all of them were stage IV at baseline. Seven (50.0%) patients had received first-line platinum-based chemotherapy or afatinib treatment, and the others had received at least 2 lines of prior therapy (range, 2-6). At the last follow-up time July 14, 2020, among these 14 evaluable patients, the ORR was 35.7% (5/14), and it showed no difference between patients with or without brain metastases (ORR, 40.0% vs. 33.3%; median PFS, 6.6 vs. 8.0 months, P = 0.623). All subgroups of patients (10 with exon 20 insertions, 2 with missense mutations and 2 with amplifications) showed disease control with a DCR of 100%. The median PFS, DoR and OS were 8.0 (95%CI: 5.8-10.2), 5.3 (95%CI: 3.6-7.0) and 12.9 (95%CI: 3.8-22.0) months, respectively. The ORR in patients who administered pyrotinib with apatinib as second-line and third- or above-line treatment was 28.6% (2/7) and 42.9% (3/7), respectively; and median PFS did not differ in these two subgroups [8.8 (95%CI: 6.6-11.0) vs. 6.1 (95%CI: 4.0-8.2) months; HR=0.362; P = 0.144]. Common treatment-related adverse events included diarrhea (7.1%, grade 3; 64.3%, grade 2), hypertension (21.4%, grade 2; 50.0%, grade 1) and anorexia (57.1%, grade 1). No treatment-related deaths were reported.
Patient characteristics at baseline and response for pyrotinib with apatinib
ConclusionParameters
Groups
N (%)
Age
>60
2 (14.3)
≤60
12 (85.7)
Gender
Male
7 (50.0)
Female
7 (50.0)
Molecular variant
A775_G776insYVMA
9 (64.3)
P780_Y781insGSP
1 (7.1)
G776V
1 (7.1)
R811L with Q820K
1 (7.1)
HER2 amplification
2 (14.4)
Prior lines of treatment
1
7 (50.0)
2
3 (21.4)
≥3
4 (28.6)
Brain metastases
Presence
5 (35.7)
Absence
9 (64.3)
Partial response
G766V
HER2 amplification
A775_G776insYVMA
1 (7.1)
1 (7.1)
3 (21.4)
Pyrotinib in combination with apatinib showed favorable antitumor activity and acceptable safety in heavily pretreated NSCLC patients with diverse HER2 mutations.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
P04 - Early Stage/Localized Disease - Perioperative Therapy (Neoadjuvant Therapy, Surgery, Adjuvant Therapy) (ID 113)
- Event: WCLC 2020
- Type: Posters
- Track: Early Stage/Localized Disease
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P04.10 - Relapsed or Metastatic Organotropism in Early Stage Lung Cancer after Radical Surgery (ID 3781)
00:00 - 00:00 | Author(s): Yan Wang
- Abstract
Introduction
Malignancies can spread to different sites in the body and the pattern which describes this phenomenon is called metastatic organotropism. Several studies had been tried to illustrate the relation between clinical or pathological features and specific metastatic sties. However, the conclusions remain controversial.
Methods
We retrospectively reviewed medical records of 2898 resected early stage non-small cell lung cancer (stage IA-IB, AJCC 7th) patients at Cancer Hospital, Chinese Academy of Medical Sciences from October 2012 to December 2015. To track the recurrence time and status, follow up had been done and the last follow up date was August 5th, 2020. Logistic regression was used to explore the relation between clinicopathological features and metastatic sites in patients who relapsed after radical surgery and especially in those who had not undergone adjuvant therapies.
Results
Among 2898 stage I non-small cell lung cancer(NSCLC) patients with surgical resection, 212(7.3%) patients relapsed, including 146 patients who had not undergone adjuvant therapies. Clinical features such as age, sex, smoking history, tumor size, tumor location, pathological factors such as pathologic type, differentiation, predominant subtype, lymphovascular space invasion(LVSI), pleural invasion and molecular mutations were included in the regression model. Distant organs were defined as metastases to bone, brain, liver and other sites except for metastases within lung and pleura. Patients with tumors in left lobes had more probabilities to metastasize to distant organs than those with tumors located in right lobes (OR=2.030, p=0.012). Among patients without adjuvant therapies, compared to lung metastases, patients with LVSI were more inclined to have brain as their first metastatic site than those without LVSI (OR=10.290, p=0.025). And compared to bone metastases, patients with pleural invasion had more tendency toward lung metastases than patients without pleural invasion (OR=5.327, p=0.026). Driver mutations, pathologic predominant subtype and adjuvant chemotherapy did not show correlation with relapsed organotropism of early stage NSCLC in our cohort.
Conclusion
We found 7.3% of stage I non-small cell lung cancer patients relapsed after radical surgery. Patients with tumors in left lobes were more likely to metastasize to distant organs. For patients who had not undergone adjuvant therapies, patients with lymphovascular space invasion of their tumors tended to metastasize to the brain and patients with pleural invasion of primary tumors tended to metastasize within the lung.
-
+
P35 - Pathology - Genomics (ID 105)
- Event: WCLC 2020
- Type: Posters
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P35.17 - Novel Genetic Characteristics in Low-Grade Fetal Adenocarcinoma of the Lung (ID 3521)
00:00 - 00:00 | Author(s): Yan Wang
- Abstract
Introduction
Low-grade fetal adenocarcinoma of the lung (L-FLAC) is a rare subtype of lung adenocarcinoma with undetermined histological features and genetic abnormalities. In this study, we attempted to investigate the pathologic characteristics and the genomic profiles of L-FLAC.
Methods
Among 9839 cases of primary lung adenocarcinoma resected at Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College between January 2011 and June 2016, 3 cases diagnosed with L-FLAC were selected. All these cases were conducted with immunohistochemical profile and the whole exome sequencing (WES) using tumor and normal tissues. Last follow-up date was July 2018.
Results
Three cases diagnosed as L-FLAC were finally screened, suggesting that the percentage of L-FLAC in lung adenocarcinoma was 0.03%. All three patients were male and were all diagnosed as stage I with radical lobectomy. The missense variant was found as the major gene mutation type in the WES testing. CTNNB1 and DICER1 were the two most frequent gene mutations. All cases demonstrated positive expression of TTF-1. In addition, two patients showed positive expression of β-Catenin, CgA and Sny. Negative expression of PD-L1 in tumor cells were observed in the three cases. One case with relatively high tumor mutation burden (TMB) (2.18 mut/mb) had an inferior overall-survival of 11.5 months. However, other two cases with lower TMB (0.12 and 0.74 mut/mb) still acquired disease-free status up to the last follow-up date.
Conclusion
L-FLAC has specific molecular background, which is different from lung adenocarcinoma. Furthermore, gene heterogeneity was found and might be the reason of dramatically different prognosis in these L-FLAC patients.
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR (ID 253)
- Event: WCLC 2020
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P76.58 - Osimertinib for EGFR-Positive NSCLC Patients with Leptomeningeal Metastases Harboring T790M-Positive or T790M-Negative Mutations (ID 3203)
00:00 - 00:00 | Author(s): Yan Wang
- Abstract
Introduction
Leptomeningeal metastasis (LM) is a catastrophic complication with poor prognosis. The efficacy of osimertinib 80mg once daily for epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with LM has not yet been fully assessed. This study aims to investigate the response to osimertinib in pretreated patients with LM regardless of T790M status, and as well, the gene profile at the diagnosis of LM was analyzed.
Methods
Between Jan 2016 and Apr 2020, EGFRm NSCLC patients who had been pretreated and progressed with cytologically confirmed symptomatic LM were retrospectively included and received osimertinib 80mg once daily. Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were evaluated. OS defined as the diagnosis of LM to death or final follow-up. Next-generation sequencing (NGS) testing was performed simultaneously on paired samples of cerebrospinal fluid and plasma at LM diagnosis
Results
Forty cases of EGFRm adenocarcinoma with LM were analyzed. 75.0% of patients were female. 37.5% had a poor ECOG score (≥2). 12 patients had received at least two prior lines of treatment. All patients received osimertinib treatment regardless of T790M status. The ORR and DCR of RANO-LM criteria by the investigator were 20.0% and 95.0%. Median PFS and OS was 9.1 (95%CI 7.1-11.1) and 15.1 (95%CI 11.0-19.4) months, respectively. The efficacy of osimertinib in T790M-negative patients (n=25) with LM was similar to that in T790M-positive ones [n=15, PFS, 10.8 (95%CI, 9.0-12.5) vs. 8.0 (95%CI 5.3-10.6) months, P = 0.072; OS, 17.2 (95%CI, 3.1-31.3) vs. 11.4 (95%CI 4.3-18.6) months, P = 0.057]. The consistency of T790M mutation testing in cerebrospinal fluid and plasma samples was only 75% (5 cases of plasma and cerebrospinal fluid samples were positive, and 25 were both negative) and the incidence of T790M in cerebrospinal fluid was lower than that in plasma (20.0% and 30.0%, P = 0.025).
Table1. Baseline patients’ characteristics
ConclusionCharacteristics
Number (40)
Age (y, %)
≥60
<60
19 (47.5)
21 (52.5)
Gender (%)
Male
Female
10 (25.0)
30 (75.0)
Smoking history (%)
Former/current
Never
9 (22.5)
31 (77.5)
Histology (%)
Adenocarcinoma
40 (100)
ECOG score (%)
0-1
≥2
25 (62.5)
15 (37.5)
Coexisting brain metastases (%)
Yes
No
35 (87.5)
5 (12.5)
Primary EGFR-sensitive mutations (%)
19 deletion
21 L858R
Compound mutations
15 (37.5)
23 (57.5)
2 (5.0)
Prior EGFR-TKIs treatment (%)
Gefitinib
Erlotinib
Icotinib
12 (30.0)
15 (37.5)
13 (32.5)
Prior chemotherapy (%)
First-line
Second-line or above
6 (15.0)
6 (15.0)
Whole-brain radiotherapy (%)
Yes
No
15 (37.5)
25 (62.5)
Intrathecal treatment (%)
>4 times
≤4 times
26 (65.0)
14 (35.0)
Treatment of cerebral edema with bevacizumab (%)
0 times
1-2 times
21 (52.5)
19 (47.5%)
T790M status (%)
Positive
Plasma only
Cerebrospinal fluid only
Plasma and cerebrospinal fluid
Negative
15 (37.5)
7 (17.5)
3 (7.5)
5 (12.5)
25 (62.5)
Osimertinib 80mg once daily presented good efficacy in pretreated EGFRm NSCLC patients with LM regardless of T790M status. Combined detection of cerebrospinal fluid and plasma testing could reveal more mechanisms of EGFR-tyrosine kinase inhibitors(TKIs) resistance.
-
+
P86 - Targeted Therapy - Clinically Focused - New Target (ID 263)
- Event: WCLC 2020
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P86.02 - Pyrotinib Combined with Apatinib for HER2-Mutant Non-Small Cell Lung Cancer: Interim Analysis from a Phase II Clinical Study (ID 3019)
00:00 - 00:00 | Presenting Author(s): Yan Wang
- Abstract
- Presentation
Introduction
Currently, there has been no approved tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC) harboring HER2 mutations, resulting in an unmet need of this molecular entity. We performed this phase II study to assess the efficacy and safety of pyrotinib combined with apatinib in HER2-mutant advanced NSCLC patients who had failed to prior treatment.
Methods
Patients with metastatic HER2-mutant lung adenocarcinomas who had been pretreated with chemotherapy or other TKIs were enrolled to administer pyrotinib (dose of 400mg once daily) in combination with apatinib (dose of 250mg once daily) for 28-day cycles. The primary endpoint was objective response rate (ORR), and the second endpoint included progression-free survival (PFS), duration of response (DoR), disease control rate (DCR), overall survival (OS) and safety. The trial was approved by ethics committee and registered to Chinese Clinical Trial Registry (ChiCTR1900021684). All participants of this study provided written informed consent.
Results
Between March 5, 2019, and January 20, 2020, 14 patients were enrolled and received pyrotinib with apatinib combination therapy, and all of them were stage IV at baseline. Seven (50.0%) patients had received first-line platinum-based chemotherapy or afatinib treatment, and the others had received at least 2 lines of prior therapy (range, 2-6). At the last follow-up time July 14, 2020, among these 14 evaluable patients, the ORR was 35.7% (5/14), and it showed no difference between patients with or without brain metastases (ORR, 40.0% vs. 33.3%; median PFS, 6.6 vs. 8.0 months, P = 0.623). All subgroups of patients (10 with exon 20 insertions, 2 with missense mutations and 2 with amplifications) showed disease control with a DCR of 100%. The median PFS, DoR and OS were 8.0 (95%CI: 5.8-10.2), 5.3 (95%CI: 3.6-7.0) and 12.9 (95%CI: 3.8-22.0) months, respectively. The ORR in patients who administered pyrotinib with apatinib as second-line and third- or above-line treatment was 28.6% (2/7) and 42.9% (3/7), respectively; and median PFS did not differ in these two subgroups [8.8 (95%CI: 6.6-11.0) vs. 6.1 (95%CI: 4.0-8.2) months; HR=0.362; P = 0.144]. Common treatment-related adverse events included diarrhea (7.1%, grade 3; 64.3%, grade 2), hypertension (21.4%, grade 2; 50.0%, grade 1) and anorexia (57.1%, grade 1). No treatment-related deaths were reported.
Patient characteristics at baseline and response for pyrotinib with apatinib
ConclusionParameters
Groups
N (%)
Age
>60
2 (14.3)
≤60
12 (85.7)
Gender
Male
7 (50.0)
Female
7 (50.0)
Molecular variant
A775_G776insYVMA
9 (64.3)
P780_Y781insGSP
1 (7.1)
G776V
1 (7.1)
R811L with Q820K
1 (7.1)
HER2 amplification
2 (14.4)
Prior lines of treatment
1
7 (50.0)
2
3 (21.4)
≥3
4 (28.6)
Brain metastases
Presence
5 (35.7)
Absence
9 (64.3)
Partial response
G766V
HER2 amplification
A775_G776insYVMA
1 (7.1)
1 (7.1)
3 (21.4)
Pyrotinib in combination with apatinib showed favorable antitumor activity and acceptable safety in heavily pretreated NSCLC patients with diverse HER2 mutations.
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
